Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.01−0.09 (-8.18%)
Close on Nov 17, 2026Market cap $13.47MP/E –Yield 0.00%
Tvardi Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Tvardi Therapeutics's total assets was $17.52M at Jun 30, 2026. For fiscal 2025 it was $32.07M, down 8.9% from the year before. Over ten years it grew -11.7% a year on average. The highest annual figure on record is $271.16M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.07M | -8.9% |
| FY2024 | Dec 31, 2024 | $35.20M | -72.0% |
| FY2023 | Dec 31, 2023 | $125.84M | -30.9% |
| FY2022 | Dec 31, 2022 | $182.24M | -26.2% |
| FY2021 | Dec 31, 2021 | $247.06M | -8.9% |
| FY2020 | Dec 31, 2020 | $271.16M | +16.4% |
| FY2019 | Dec 31, 2019 | $232.96M | +22.1% |
| FY2018 | Dec 31, 2018 | $190.82M | +96.7% |
| FY2017 | Dec 31, 2017 | $97.00M | +52.0% |
| FY2016 | Dec 31, 2016 | $63.83M | -42.4% |
| FY2015 | Dec 31, 2015 | $110.90M | +98.3% |
| FY2014 | Dec 31, 2014 | $55.93M | +209.3% |
| FY2013 | Dec 31, 2013 | $18.08M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.52M | -60.0% |
| Q1 FY2026 | Mar 31, 2026 | $25.82M | -33.7% |
| Q4 FY2025 | Dec 31, 2025 | $32.07M | -8.9% |
| Q3 FY2025 | Sep 30, 2025 | $39.02M | -24.0% |
| Q2 FY2025 | Jun 30, 2025 | $43.75M | -39.7% |
| Q1 FY2025 | Mar 31, 2025 | $38.95M | -56.8% |
| Q4 FY2024 | Dec 31, 2024 | $35.20M | -72.0% |
| Q3 FY2024 | Sep 30, 2024 | $51.33M | -55.5% |
| Q2 FY2024 | Jun 30, 2024 | $72.50M | -46.1% |
| Q1 FY2024 | Mar 31, 2024 | $90.10M | -41.2% |
| Q4 FY2023 | Dec 31, 2023 | $125.84M | -30.9% |
| Q3 FY2023 | Sep 30, 2023 | $115.34M | -46.0% |
| Q2 FY2023 | Jun 30, 2023 | $134.39M | -40.7% |
| Q1 FY2023 | Mar 31, 2023 | $153.28M | -31.5% |
| Q4 FY2022 | Dec 31, 2022 | $182.24M | -26.2% |
| Q3 FY2022 | Sep 30, 2022 | $213.51M | -5.1% |
| Q2 FY2022 | Jun 30, 2022 | $226.57M | +2.3% |
| Q1 FY2022 | Mar 31, 2022 | $223.87M | -10.5% |
| Q4 FY2021 | Dec 31, 2021 | $247.06M | -8.9% |
| Q3 FY2021 | Sep 30, 2021 | $225.09M | +53.0% |
| Q2 FY2021 | Jun 30, 2021 | $221.45M | +31.3% |
| Q1 FY2021 | Mar 31, 2021 | $250.23M | +27.6% |
| Q4 FY2020 | Dec 31, 2020 | $271.16M | +16.4% |
| Q3 FY2020 | Sep 30, 2020 | $147.14M | -44.2% |
| Q2 FY2020 | Jun 30, 2020 | $168.61M | +12.7% |
| Q1 FY2020 | Mar 31, 2020 | $196.17M | +15.0% |
| Q4 FY2019 | Dec 31, 2019 | $232.96M | +22.1% |
| Q3 FY2019 | Sep 30, 2019 | $263.80M | +24.0% |
| Q2 FY2019 | Jun 30, 2019 | $149.64M | +7.0% |
| Q1 FY2019 | Mar 31, 2019 | $170.59M | +111.6% |
| Q4 FY2018 | Dec 31, 2018 | $190.82M | +96.7% |
| Q3 FY2018 | Sep 30, 2018 | $212.70M | +96.9% |
| Q2 FY2018 | Jun 30, 2018 | $139.89M | +18.6% |
| Q1 FY2018 | Mar 31, 2018 | $80.64M | +86.2% |
| Q4 FY2017 | Dec 31, 2017 | $97.00M | +52.0% |
| Q3 FY2017 | Sep 30, 2017 | $108.05M | +34.8% |
| Q2 FY2017 | Jun 30, 2017 | $117.97M | – |
| Q1 FY2017 | Mar 31, 2017 | $43.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $63.83M | – |
| Q3 FY2016 | Sep 30, 2016 | $80.15M | – |
See a number that looks wrong?